PL2872176T3 - Karboranyloporfiryny do stosowania w leczeniu raka - Google Patents

Karboranyloporfiryny do stosowania w leczeniu raka

Info

Publication number
PL2872176T3
PL2872176T3 PL13737828T PL13737828T PL2872176T3 PL 2872176 T3 PL2872176 T3 PL 2872176T3 PL 13737828 T PL13737828 T PL 13737828T PL 13737828 T PL13737828 T PL 13737828T PL 2872176 T3 PL2872176 T3 PL 2872176T3
Authority
PL
Poland
Prior art keywords
carboranylporphyrins
cancer
treatment
Prior art date
Application number
PL13737828T
Other languages
English (en)
Inventor
Christopher Beattie
Anne Wadsworth
James Rennie
Original Assignee
Morex Dev Partners Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morex Dev Partners Llp filed Critical Morex Dev Partners Llp
Publication of PL2872176T3 publication Critical patent/PL2872176T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13737828T 2012-07-12 2013-07-11 Karboranyloporfiryny do stosowania w leczeniu raka PL2872176T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1212409.5A GB201212409D0 (en) 2012-07-12 2012-07-12 Cancer treatment

Publications (1)

Publication Number Publication Date
PL2872176T3 true PL2872176T3 (pl) 2017-09-29

Family

ID=46766538

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13737828T PL2872176T3 (pl) 2012-07-12 2013-07-11 Karboranyloporfiryny do stosowania w leczeniu raka

Country Status (17)

Country Link
US (1) US9750809B2 (pl)
EP (2) EP2872176B1 (pl)
JP (1) JP6170147B2 (pl)
KR (1) KR20150036574A (pl)
CN (1) CN104602710A (pl)
CA (1) CA2878480A1 (pl)
CY (1) CY1120075T1 (pl)
DK (1) DK2872176T3 (pl)
ES (1) ES2627819T3 (pl)
GB (1) GB201212409D0 (pl)
HK (1) HK1210023A1 (pl)
HU (1) HUE033330T2 (pl)
LT (1) LT2872176T (pl)
PL (1) PL2872176T3 (pl)
PT (1) PT2872176T (pl)
SI (1) SI2872176T1 (pl)
WO (1) WO2014009496A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201221125D0 (en) 2012-11-23 2013-01-09 Morex Dev Partners Llp Pharmaceutial formulations
CN105233283B (zh) * 2015-11-11 2021-06-11 广西康健奥鑫生物医药科技有限公司 一种光动力治疗深部肿瘤靶向纳米光敏剂及其制备方法
RU2689623C1 (ru) * 2018-12-18 2019-05-28 Акционерное общество "НИПИгазпереработка" (АО "НИПИГАЗ") Установка подготовки газа
CN112473024B (zh) * 2020-11-30 2021-09-14 南京航空航天大学 一种对bnct过程中的三维硼剂量或硼浓度进行实时监测的方法
CN114344736B (zh) * 2021-12-09 2022-09-13 吉林大学 一种包含体内光核反应的肿瘤治疗系统及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2310447C2 (ru) 2001-06-06 2007-11-20 Брукхейвен Сайенс Ассошиэйтс Новые металлопорфирины и их применение в качестве радиосенсибилизаторов в лучевой терапии
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
US7267990B2 (en) * 2002-11-15 2007-09-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chelation of charged and uncharged molecules with porphyrin-based compounds
US20070093463A1 (en) * 2004-05-20 2007-04-26 Brookhaven Science Associates, Llc Radiation enhancement agent for X-ray radiation therapy and boron neutron-capture therapy
US6989443B2 (en) 2004-06-28 2006-01-24 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
JP4972929B2 (ja) 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
WO2007050564A2 (en) 2005-10-25 2007-05-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Boron-containing porphyrin compounds and their uses
US8287839B2 (en) 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
GB201221125D0 (en) * 2012-11-23 2013-01-09 Morex Dev Partners Llp Pharmaceutial formulations

Also Published As

Publication number Publication date
LT2872176T (lt) 2017-07-10
KR20150036574A (ko) 2015-04-07
EP3205354A1 (en) 2017-08-16
JP6170147B2 (ja) 2017-07-26
PT2872176T (pt) 2017-06-21
WO2014009496A1 (en) 2014-01-16
US9750809B2 (en) 2017-09-05
GB201212409D0 (en) 2012-08-22
HK1210023A1 (en) 2016-04-15
CN104602710A (zh) 2015-05-06
EP2872176A1 (en) 2015-05-20
EP2872176B1 (en) 2017-03-22
SI2872176T1 (sl) 2017-08-31
ES2627819T3 (es) 2017-07-31
US20150157712A1 (en) 2015-06-11
CA2878480A1 (en) 2014-01-16
CY1120075T1 (el) 2018-12-12
DK2872176T3 (en) 2017-06-19
HUE033330T2 (en) 2017-11-28
JP2015524795A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
IL267242B (en) Cancer treatment
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL239007B (en) Eribulin for use in the treatment of breast cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
HK1210023A1 (en) Cancer treatment
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201222563D0 (en) Cancer treatment
EP3104863C0 (en) SALICYLATE FOR USE IN THE TREATMENT OF CANCER
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer